| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
33,442 |
22,524 |
$363K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
33,319 |
23,087 |
$202K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
571 |
454 |
$21K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
1,724 |
1,425 |
$10K |
| G0482 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed |
657 |
553 |
$7K |
| 64493 |
|
155 |
57 |
$5K |
| 64494 |
|
157 |
57 |
$1K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
1,166 |
830 |
$1K |
| 99152 |
|
475 |
363 |
$995.40 |
| 62323 |
|
32 |
12 |
$711.78 |
| 64495 |
|
34 |
12 |
$685.84 |
| 64635 |
|
16 |
12 |
$650.67 |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
829 |
257 |
$331.30 |
| 64636 |
|
18 |
12 |
$240.63 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
1,015 |
698 |
$196.88 |
| 99205 |
Prolong outpt/office vis |
27 |
12 |
$154.98 |
| 95886 |
|
26 |
12 |
$150.62 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
738 |
543 |
$111.47 |
| G0481 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed |
98 |
92 |
$0.00 |
| 1036F |
|
399 |
379 |
$0.00 |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
16 |
13 |
$0.00 |
| 97140 |
Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) |
27 |
12 |
$0.00 |
| G8420 |
Bmi is documented within normal parameters and no follow-up plan is required |
28 |
28 |
$0.00 |
| 97530 |
Therapeutic activities, direct patient contact, each 15 minutes |
124 |
54 |
$0.00 |
| G8730 |
Pain assessment documented as positive using a standardized tool and a follow-up plan is documented |
547 |
517 |
$0.00 |
| G8427 |
Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications |
549 |
519 |
$0.00 |
| G8417 |
Bmi is documented above normal parameters and a follow-up plan is documented |
423 |
401 |
$0.00 |
| L0650 |
Lumbar-sacral orthosis, sagittal-coronal control, with rigid anterior and posterior frame/panel(s), posterior extends from sacrococcygeal junction to t-9 vertebra, lateral strength provided by rigid lateral frame/panel(s), produces intracavitary pressure to reduce load on intervertebral discs, includes straps, closures, may include padding, shoulder straps, pendulous abdomen design, prefabricated, off-the-shelf |
14 |
13 |
$0.00 |
| 4004F |
|
19 |
19 |
$0.00 |